Research Solutions Inc. reports Q1 net income of $749,000 and 21% ARR growth

Reuters
Nov 14, 2025
Research Solutions Inc. reports Q1 net income of $749,000 and 21% ARR growth

Research Solutions Inc. reported financial results for its fiscal first quarter ended September 30, 2025. Total revenue increased by 2.2% to $12.3 million compared to $12.0 million in the prior-year quarter. Platform revenue rose 18.3% to $5.1 million, representing 42% of total revenue, while Transactions revenue declined 6.8% to $7.2 million. Gross profit grew by 8.0% to $6.2 million. Annual Recurring Revenue $(ARR)$ increased by 21% to $21.3 million, with $14.8 million from B2B recurring revenue and $6.5 million from B2C recurring revenue. Net income was $749,000, or $0.02 per diluted share, up from $669,000, or $0.02 per diluted share, in the prior-year quarter. Adjusted EBITDA was $1.5 million, compared to $1.3 million in the same period last year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Research Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA24129) on November 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10